Top

Published in:

Open Access 01-12-2023 | Diabetes | Research

Serum anti-PCK1 antibody levels are a prognostic factor for patients with diabetes mellitus

Authors: Toshiki Namiki, Minoru Takemoto, Aiko Hayashi, Hiroki Yamagata, Takahiro Ishikawa, Koutaro Yokote, Shu-Yang Li, Masaaki Kubota, Bo-Shi Zhang, Yoichi Yoshida, Tomoo Matsutani, Seiichiro Mine, Toshio Machida, Yoshio Kobayashi, Jiro Terada, Akira Naito, Koichiro Tatsumi, Hirotaka Takizawa, Rika Nakamura, Hideyuki Kuroda, Yasuo Iwadate, Takaki Hiwasa

Published in: BMC Endocrine Disorders | Issue 1/2023

Abstract

Background

Autoantibodies develop in autoimmune diseases, cancer, diabetes mellitus (DM), and atherosclerosis-related diseases. However, autoantibody biomarkers have not been successfully examined for diagnosis and therapy.

Methods

Serological identification of antigens through recombinant cDNA expression cloning (SEREX) was used for primary screening of antigens. The cDNA product was expressed in bacteria and purified. Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) was used to evaluate antibody levels in serum samples.

Results

Phosphoenolpyruvate carboxykinase 1 (PCK1) was recognized as an antigen by serum IgG antibodies in the sera of patients with atherosclerosis. AlphaLISA showed significantly higher serum antibody levels against recombinant PCK1 protein in patients with DM and cardiovascular disease than in healthy donors, but not in those with acute ischemic stroke, transient ischemic attack, or obstructive sleep apnea syndrome. The area under the receiver operating characteristic curve for anti-PCK1 antibodies was 0.7024 for DM. The serum anti-PCK1 antibody levels were associated with age, platelet count, and blood pressure. Anti-PCK1-antibody-positive patients showed significantly lower overall survival than the negative patients.

Conclusions

Serum anti-PCK1 antibody levels were found to be associated with DM. The anti-PCK1 antibody marker is useful for predicting the overall survival of patients with DM.

Available only for authorised users

Ali MK, Siegel KR, Chandrasekar E, Tandon N, Montoya PA, Mbanya JC, et al. Diabetes: an update on the pandemic and potential solutions. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors., et al., Cardiovascular, respiratory, and related disorders. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017.

Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21:21. https://doi.org/10.1007/s11886-019-1107-y.CrossRefPubMed

Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999-2018. N Engl J Med. 2021;384:2219–28. https://doi.org/10.1056/NEJMsa2032271.CrossRefPubMedPubMedCentral

Yoshida Y, Hiwasa T, Machida T, Kobayashi E, Mine S, Matsushima J, et al. Elevation of autoantibody in patients with ischemic stroke. Neurol Med Chir (Tokyo). 2018;58:303–10. https://doi.org/10.2176/nmc.ra.2018-0022.CrossRefPubMed

Yoshida Y, Wang H, Hiwasa T, Machida T, Kobayashi E, Mine S, et al. Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack. Oncotarget. 2018;9:8836–48. https://doi.org/10.18632/oncotarget.23653.CrossRefPubMed

Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, et al. Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea. PLoS ONE. 2018;13:e0195015. https://doi.org/10.1371/journal.pone.0195015.CrossRefPubMedPubMedCentral

Katsumata Y, Terada J, Matsumura T, Koshikawa K, Sakao S, Tomiyoshi G, et al. Circulating anti-sorting nexins 16 antibodies as an emerging biomarker of coronary artery disease in patients with obstructive sleep apnea. Diagnostics (Basel). 2020;10:71. https://doi.org/10.3390/diagnostics10020071.CrossRefPubMed

Yoshida Y, Zhang XM, Wang H, Machida T, Mine S, Kobayashi E, et al. Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. Heliyon. 2020;6:e04661. https://doi.org/10.1016/j.heliyon.2020.e04661.CrossRefPubMedPubMedCentral

Wang H, Zhang XM, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, et al. Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget. 2018;9:5600–13. https://doi.org/10.18632/oncotarget.23789.CrossRefPubMed

10.

Li SY, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, et al. Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Sci Rep. 2021;11:13450. https://doi.org/10.1038/s41598-021-92786-9.CrossRefPubMedPubMedCentral

11.

Hiwasa T, Wang H, Goto KI, Mine S, Machida T, Kobayashi E, et al. Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Med. 2021;19:131. https://doi.org/10.1186/s12916-021-02001-9.CrossRefPubMedPubMedCentral

12.

Machida T, Kubota M, Kobayashi E, Iwadate Y, Saeki N, Yamaura A, et al. Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX). J Transl Med. 2015;13:71. https://doi.org/10.1186/s12967-015-0393-4.CrossRefPubMedPubMedCentral

13.

Huang H, Liu J, Liang X, Fang L, Yang C, Ke K, et al. Trends in the prevalence of elevated cardiovascular risk and the control of its risk factors among US adults, 2001–2020. Front Cardiovasc Med. 2023;10:1153926. https://doi.org/10.3389/fcvm.2023.1153926.CrossRefPubMedPubMedCentral

14.

Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28. https://doi.org/10.1111/j.2040-1124.2010.00074.x.CrossRefPubMedPubMedCentral

15.

Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, et al. Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies as a potential biomarker for cardiovascular and cerebrovascular events in patients with obstructive sleep apnea. J Clin Sleep Med. 2017;13:393–400. https://doi.org/10.5664/jcsm.6488.CrossRefPubMedPubMedCentral

16.

Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35–41. https://doi.org/10.1161/01.str.24.1.35.CrossRefPubMed

17.

Li SY, Yoshida Y, Kobayashi E, Adachi A, Hirono S, Matsutani T, et al. Association between serum anti-ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. Int J Mol Med. 2020;46:1274–88. https://doi.org/10.3892/ijmm.2020.4690.CrossRefPubMedPubMedCentral

18.

Sumazaki M, Shimada H, Ito M, Shiratori F, Kobayashi E, Yoshida Y, et al. Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Sci. 2020;111:4453–64. https://doi.org/10.1111/cas.14652.CrossRefPubMedPubMedCentral

19.

Pilz AJ, Willer E, Povey S, Abbott CM. The genes coding for phosphoenolpyruvate carboxykinase-1 (PCK1) and neuronal nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4) map to human chromosome 20, extending the known region of homology with mouse chromosome 2. Ann Hum Genet. 1992;56:289–93. https://doi.org/10.1111/j.1469-1809.1992.tb01155.x.CrossRefPubMed

20.

Modaressi S, Brechtel K, Christ B, Jungermann K. Human mitochondrial phosphoenolpyruvate carboxykinase 2 gene. Structure, chromosomal localization and tissue-specific expression. Biochem J. 1998;333:359–66. https://doi.org/10.1042/bj3330359.CrossRefPubMedPubMedCentral

21.

Suzuki M, Yamasaki T, Shinohata R, Hata M, Nakajima H, Kono N. Cloning and reporter analysis of human mitochondrial phosphoenolpyruvate carboxykinase gene promoter. Gene. 2004;338:157–62. https://doi.org/10.1016/j.gene.2004.06.005.CrossRefPubMed

22.

Yang J, Kalhan SC, Hanson RW. What is the metabolic role of phosphoenolpyruvate carboxykinase? J Biol Chem. 2009;284:27025–9. https://doi.org/10.1074/jbc.R109.040543.CrossRefPubMedCentral

23.

Hakimi P, Johnson MT, Yang J, Lepage DF, Conlon RA, Kalhan SC, et al. Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the control of hepatic metabolism. Nutr Metab (Lond). 2005;2:33. https://doi.org/10.1186/1743-7075-2-33.CrossRefPubMed

24.

Semakova J, Hyrossova P, Mendez-Lucas A, Cutz E, Bermudez J, Burgess S, et al. PEPCK-C reexpression in the liver counters neonatal hypoglycemia in Pck1 (del/del) mice, unmasking role in non-gluconeogenic tissues. J Physiol Biochem. 2017;73:89–98. https://doi.org/10.1007/s13105-016-0528-y.CrossRefPubMed

25.

Franckhauser S, Munoz S, Elias I, Ferre T, Bosch F. Adipose overexpression of phosphoenolpyruvate carboxykinase leads to high susceptibility to diet-induced insulin resistance and obesity. Diabetes. 2006;55:273–80. https://doi.org/10.2337/diabetes.55.02.06.db05-0482.CrossRefPubMed

26.

Cao H, van der Veer E, Ban MR, Hanley AJ, Zinman B, Harris SB, et al. Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:898–903. https://doi.org/10.1210/jc.2003-031361.CrossRefPubMed

27.

Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. Association of the promoter polymorphism -232C/G of the phosphoenolpyruvate carboxykinase gene (PCK1) with type 2 diabetes mellitus. Diabet Med. 2006;23:419–25. https://doi.org/10.1111/j.1464-5491.2006.01819.x.CrossRefPubMed

28.

Rees SD, Britten AC, Bellary S, O’Hare JP, Kumar S, Barnett AH, et al. The promoter polymorphism -232C/G of the PCK1 gene is associated with type 2 diabetes in a UK-resident South Asian population. BMC Med Genet. 2009;10:83. https://doi.org/10.1186/1471-2350-10-83.CrossRefPubMed

29.

Yabaluri N, Bashyam MD. Hormonal regulation of gluconeogenic gene transcription in the liver. J Biosci. 2010;35:473–84. https://doi.org/10.1007/s12038-010-0052-0.CrossRefPubMed

30.

Ciardullo S, Perseghin G. Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999–2016. Liver Int. 2022;43:340–4. https://doi.org/10.1111/liv.15503.CrossRefPubMed

31.

Hegele RA, Al-Shali KZ, House AA, Hanley AJ, Harris SB, Mamakeesick M, et al. Disparate associations of a functional promoter polymorphism in PCK1 with carotid wall ultrasound traits. Stroke. 2005;36:2566–70. https://doi.org/10.1161/01.STR.0000190833.43791.be.CrossRefPubMed

32.

Grasmann G, Smolle E, Olschewski H, Leithner K. Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway? Biochim Biophys Acta Rev Cancer. 2019;1872:24–36. https://doi.org/10.1016/j.bbcan.2019.05.006.CrossRefPubMedPubMedCentral

Title: Serum anti-PCK1 antibody levels are a prognostic factor for patients with diabetes mellitus
Authors: Toshiki Namiki
Minoru Takemoto
Aiko Hayashi
Hiroki Yamagata
Takahiro Ishikawa
Koutaro Yokote
Shu-Yang Li
Masaaki Kubota
Bo-Shi Zhang
Yoichi Yoshida
Tomoo Matsutani
Seiichiro Mine
Toshio Machida
Yoshio Kobayashi
Jiro Terada
Akira Naito
Koichiro Tatsumi
Hirotaka Takizawa
Rika Nakamura
Hideyuki Kuroda
Yasuo Iwadate
Takaki Hiwasa
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Diabetes
Arterial Occlusive Disease
Biomarkers
Published in: BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-023-01491-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Association between a high triglyceride–glucose index and chronic kidney disease in adult patients with latent autoimmune diabetes

Prevalence of osteoporosis in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies

The nonlinear correlation between alanine aminotransferase to high-density lipoprotein cholesterol ratio and the risk of diabetes: a historical Japanese cohort study

Treatment of septic shock in two pediatric patients with severe diabetic ketoacidosis using invasive hemodynamic monitoring: a case report

Serum homocysteine concentration as a marker for advanced diabetic nephropathy in a cohort of elderly patients

Soluble receptor for advanced glycation end products (sRAGE) is associated with obesity rates: a systematic review and meta-analysis of cross-sectional study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials